Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Wee1 siRNA effects on cell line panel

From: Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells

Cell line Cancer origin TP53 status % viability
A2780 Ovary WT 98
A549 Lung WT 102
D54MG Glioma WT 93
HCT-116 Colon WT 74
MCF-7 Breast WT 65
U87MG Glioblastoma WT 42
ZR-75-1 Breast WT 57
U118MG Glioblastoma R213Q 73
HCT-15 Colon S241F 98
DLD-1 Colon S241F 89
DAOY Medulloblastoma C242F 3
MiaPaca-2 Pancreas R248W 92
A431 Epidermis R273H 70
MDA-MB-231 Breast R280K 15
MDA-MB-453 Breast 368-del30 29
MDA-MB-361 Breast S166* 5
Calu-6 Lung R196* 7
HeLa Cervix Low (E6) 3
SK-N-MC Ewing’s -/- 27
H1299 Lung -/- 4
  1. Efficacy of Wee1 siRNA treatment was assayed in a panel of 20 solid human cell lines derived from various tumors. Percent viability is measured after five days by taking the average of Wee1 siRNAs #6 and #8 and comparing them to the non-targeting and Ran siRNA controls. p53 genotype data were procured from The p53 Mutation HandBook ([17]). All results are the average of a minimum of three separate experiments.